BACKGROUND: Many pediatric patients undergoingcardiac surgery involving cardiopulmonary bypass have a predictable fall in the cardiac index 6 to 18 hours after surgery, the so-called low cardiac output syndrome (LCOS). Because patients who have LCOS require more monitoring and support and have a prolonged stay in the intensive care unit, the syndrome is associated with a costly morbidity. Milrinone, a phosphodiesterase III inhibitor, improves cardiac muscle contractile force and vascular muscle relaxation through positive inotropic and vasodilatory effects. The purpose of the Prophylactic Intravenous Use of MilrinoneAfter Cardiac Operation in Pediatrics (PRIMACORP) study is to evaluate the safety and efficacy of the prophylactic use of milrinone in pediatric patients at high risk for development of LCOS after undergoing cardiac surgery. METHODS: Patients in the multicenter, randomized, double-blind, placebo-controlled, parallel treatment study will be randomized to 1 of 3 treatment arms: (1) low-dose milrinone (25 microg/kg intravenous bolus over 60 minutes followed by a 0.25 microg/kg/min infusion for 35 hours), (2) high-dose milrinone (75 microg/kg intravenous bolus over 60 minutes followed by a 0.75 microg/kg/min infusion for 35 hours), or (3) placebo. RESULTS: The primary end point for efficacy evaluation will be based on a composite variable consisting of death or development of LCOS requiring additional mechanical or pharmacologic support, up to 36 hours after randomization. A 2-sided test with a 0.025 type I error will be used for the primary end point analysis. The PRIMACORP study will enroll a total of 240 patients. Six additional secondary end points will be analyzed. CONCLUSIONS: The PRIMACORP study will address several questions regarding the safety and efficacy of prophylactic milrinone use in pediatric patients at high risk for development of LCOS after cardiac surgery.
RCT Entities:
BACKGROUND: Many pediatric patients undergoing cardiac surgery involving cardiopulmonary bypass have a predictable fall in the cardiac index 6 to 18 hours after surgery, the so-called low cardiac output syndrome (LCOS). Because patients who have LCOS require more monitoring and support and have a prolonged stay in the intensive care unit, the syndrome is associated with a costly morbidity. Milrinone, a phosphodiesterase III inhibitor, improves cardiac muscle contractile force and vascular muscle relaxation through positive inotropic and vasodilatory effects. The purpose of the Prophylactic Intravenous Use of Milrinone After Cardiac Operation in Pediatrics (PRIMACORP) study is to evaluate the safety and efficacy of the prophylactic use of milrinone in pediatric patients at high risk for development of LCOS after undergoing cardiac surgery. METHODS:Patients in the multicenter, randomized, double-blind, placebo-controlled, parallel treatment study will be randomized to 1 of 3 treatment arms: (1) low-dose milrinone (25 microg/kg intravenous bolus over 60 minutes followed by a 0.25 microg/kg/min infusion for 35 hours), (2) high-dose milrinone (75 microg/kg intravenous bolus over 60 minutes followed by a 0.75 microg/kg/min infusion for 35 hours), or (3) placebo. RESULTS: The primary end point for efficacy evaluation will be based on a composite variable consisting of death or development of LCOS requiring additional mechanical or pharmacologic support, up to 36 hours after randomization. A 2-sided test with a 0.025 type I error will be used for the primary end point analysis. The PRIMACORP study will enroll a total of 240 patients. Six additional secondary end points will be analyzed. CONCLUSIONS: The PRIMACORP study will address several questions regarding the safety and efficacy of prophylactic milrinone use in pediatric patients at high risk for development of LCOS after cardiac surgery.
Authors: Andrea Székely; Tamás Breuer; Erzsébet Sápi; Edgár Székely; András Szatmári; Miklós Tóth; Balázs Hauser; János Gál Journal: Pediatr Cardiol Date: 2011-02 Impact factor: 1.655
Authors: Stephanie J Nakano; Shelley D Miyamoto; Matthew Movsesian; Penny Nelson; Brian L Stauffer; Carmen C Sucharov Journal: Circ Heart Fail Date: 2014-10-02 Impact factor: 8.790
Authors: Wyman W Lai; Victoria L Vetter; Marc Richmond; Jennifer S Li; J Philip Saul; Seema Mital; Steven D Colan; Jane W Newburger; Lynn A Sleeper; Brian W McCrindle; L Luann Minich; Elizabeth Goldmuntz; Bradley S Marino; Ismee A Williams; Gail D Pearson; Frank Evans; Jane D Scott; Meryl S Cohen Journal: Am Heart J Date: 2011-01 Impact factor: 4.749
Authors: Chloë Joynt; David L Bigam; Gregory Charrois; Laurence D Jewell; Gregory Korbutt; Po-Yin Cheung Journal: Intensive Care Med Date: 2008-03-21 Impact factor: 17.440
Authors: James M Bailey; Timothy M Hoffman; David L Wessel; David P Nelson; Andrew M Atz; Anthony C Chang; Thomas J Kulik; Thomas L Spray; Akbar Akbary; Richard P Miller; Gil Wernovsky Journal: J Pharmacokinet Pharmacodyn Date: 2004-02 Impact factor: 2.745